Cardiol Competitors
| CRDL Stock | USD 0.99 0.03 3.13% |
Cardiol Therapeutics vs Hyperfine Correlation
Average diversification
The correlation between Cardiol Therapeutics Class and HYPR is 0.16 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Cardiol Therapeutics Class and HYPR in the same portfolio, assuming nothing else is changed.
Moving together with Cardiol Stock
Moving against Cardiol Stock
The value of Return On Tangible Assets is estimated to slide to -1.39. The value of Return On Capital Employed is expected to slide to -1.96. At this time, Cardiol Therapeutics' Other Current Assets are quite stable compared to the past year. Intangible Assets is expected to rise to about 362.1 K this year, although the value of Total Assets will most likely fall to about 36 M.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cardiol Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cardiol Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Cardiol Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Cardiol and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Cardiol Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Cardiol Stock performing well and Cardiol Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cardiol Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| INCR | 2.79 | (0.79) | 0.00 | (0.68) | 0.00 | 6.06 | 18.96 | |||
| CNTB | 4.53 | 0.89 | 0.14 | (0.52) | 4.33 | 11.89 | 38.27 | |||
| VANI | 3.11 | (0.34) | 0.00 | (0.45) | 0.00 | 6.99 | 18.98 | |||
| MBOT | 3.41 | (0.38) | 0.00 | (0.07) | 0.00 | 5.78 | 30.11 | |||
| NSPR | 3.39 | (0.45) | 0.00 | (0.20) | 0.00 | 6.53 | 24.29 | |||
| ASRT | 2.77 | 0.13 | 0.06 | 0.16 | 2.99 | 9.01 | 24.64 | |||
| IFRX | 4.72 | (0.66) | 0.00 | (0.19) | 0.00 | 7.84 | 43.11 | |||
| KLRS | 4.65 | 1.02 | 0.17 | (1.85) | 4.34 | 15.58 | 32.70 | |||
| IMA | 2.50 | (0.27) | 0.00 | (0.67) | 0.00 | 6.76 | 18.29 | |||
| HYPR | 4.14 | (0.04) | 0.00 | 0.05 | 4.27 | 9.09 | 18.91 |
Cross Equities Net Income Analysis
Compare Cardiol Therapeutics and related stocks such as INC Research Holdings, Connect Biopharma, and Vivani Medical Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INCR | (12.6 M) | (6.8 M) | 43.4 M | (6.6 M) | (3.8 M) | (1.9 M) | 265.4 K | (5.3 M) | (12.8 M) | (5.9 M) | (37.2 M) | 4.7 M | 44.8 M | (62 M) | (67.8 M) | (61 M) | (58 M) |
| CNTB | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (120.3 M) | (205.2 M) | (116.4 M) | (59.5 M) | (15.6 M) | (18 M) | (18.9 M) |
| VANI | (16.3 M) | (16.3 M) | (16.3 M) | (23 M) | (35.2 M) | (20 M) | (33.2 M) | (28.5 M) | (35.1 M) | (33.6 M) | (9.3 M) | (12.8 M) | (13.9 M) | (25.7 M) | (23.5 M) | (27 M) | (28.4 M) |
| MBOT | (6.4 M) | (21.3 M) | (28.5 M) | (26.4 M) | (32.7 M) | (36.4 M) | (9.7 M) | (7.6 M) | (7.3 M) | (7.2 M) | (9.2 M) | (11.3 M) | (13.2 M) | (10.7 M) | (11.4 M) | (10.3 M) | (10.8 M) |
| NSPR | (3.8 K) | (17.6 M) | (17.6 M) | (29.3 M) | (25.1 M) | (15.6 M) | (8.5 M) | (8.4 M) | (7.2 M) | (10 M) | (10.5 M) | (14.9 M) | (18.5 M) | (19.9 M) | (32 M) | (28.8 M) | (27.4 M) |
| ASRT | (500 K) | 70.7 M | (29.8 M) | 43.3 M | 131.8 M | (75.7 M) | (88.7 M) | (102.5 M) | 36.9 M | (217.2 M) | (28.1 M) | (1.3 M) | 109.6 M | (331.9 M) | (21.6 M) | (19.4 M) | (20.4 M) |
| IFRX | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (8.9 M) | (24.2 M) | (29.8 M) | (59.6 M) | (38.7 M) | (53.9 M) | (31 M) | (42.7 M) | (46.1 M) | (41.5 M) | (43.5 M) |
| KLRS | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (23.8 M) | (69.8 M) | (172 M) | (15.5 M) | (14.7 M) | (58.8 M) | (52.9 M) | (55.5 M) |
| IMA | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (16.8 M) | (44.3 M) | (34.1 M) | (68.8 M) | (68.2 M) | (36.6 M) | (32.9 M) | (34.6 M) |
| HYPR | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (23.4 M) | (64.8 M) | (73.2 M) | (44.2 M) | (40.7 M) | (36.6 M) | (38.5 M) |
Cardiol Therapeutics and related stocks such as INC Research Holdings, Connect Biopharma, and Vivani Medical Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Cardiol Therapeutics financial statement analysis. It represents the amount of money remaining after all of Cardiol Therapeutics Class operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Cardiol Therapeutics Competitive Analysis
The better you understand Cardiol Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Cardiol Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Cardiol Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Cardiol Therapeutics Competition Performance Charts
Five steps to successful analysis of Cardiol Therapeutics Competition
Cardiol Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Cardiol Therapeutics in relation to its competition. Cardiol Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Cardiol Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Cardiol Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Cardiol Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Cardiol Therapeutics position
In addition to having Cardiol Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Utilities ETFs Thematic Idea Now
Utilities ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Utilities ETFs theme has 15 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Cardiol Therapeutics Correlation with its peers. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. Projected growth potential of Cardiol fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cardiol Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Cardiol Therapeutics requires distinguishing between market price and book value, where the latter reflects Cardiol's accounting equity. The concept of intrinsic value - what Cardiol Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Cardiol Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Cardiol Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cardiol Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cardiol Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.